Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis

References

• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361.
   PubMed Web of Science ®Google Scholar
• Houge IS, Hoff M, Thomas R, et al. Mortality is increased in patients with rheumatoid arthritis or diabetes compared to the general population - the nord-trondelag health study. Sci Rep. 2020 Feb 27;10:3593.
   PubMed Web of Science ®Google Scholar
• van den Hoek J, Boshuizen HC, Roorda LD, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017 Apr;37:487–493.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75:3–15.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr;69(4):631–637.
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73:924–939.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010 Aug;40:2–14 e1.
   PubMed Web of Science ®Google Scholar
• Jin Y, Desai RJ, Liu J, et al. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Res Ther. 2017 Jul 5;19:159.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res (Hoboken). 2014 Nov;66:1604–1611.
   PubMed Web of Science ®Google Scholar
• Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010 Jan;26:77–90.
   PubMed Web of Science ®Google Scholar
• Yip S. Datamonitor healthcare. Intelligence IP editor. Subscription required for access. [cited Feb 2022]. Available from: www.pharma.id.informa.com
   Google Scholar
• Rind DM, Agboola F, Nikitin D, et al. Institute for Clinical and Economic Review. Unsupported Price Increase Report: Unsupported Price Increases Occurring in 2020; Interim Report. [cited 2021 Dec 6]. Available from: https://icer.org/assessment/unsupported-price-increase-2020/
   Google Scholar
• MicroMedex Redbook [Internet]. IBM Corporation. 2017 [cited 2022 Feb 1]. Available from: http://www.micromedexsolutions.com/
   Google Scholar
• Mellors T, Withers JB, Ameli A, et al. Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. Network Syst Med. 2020; 3: 91–104.
   Google Scholar
• Cohen S, Wells AF, Curtis JR, et al. A molecular signature response classifier to predict inadequate response to tumor necrosis factor-alpha inhibitors: the NETWORK-004 prospective observational study. Rheumatol Ther. 2021 Sep;8:1159–1176.
   PubMed Web of Science ®Google Scholar
• Jones A, Rapisardo S, Zhang L, et al. Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis. Expert Rev Mol Diagn. 2021 Nov;21:1235–1243.
   PubMed Web of Science ®Google Scholar
• Strand V, Cohen SB, Curtis JR, et al. Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-a inhibitors: an analysis from the study to accelerate information of molecular signatures (AIMS) in rheumatoid arthritis. Expert Rev Mol Diagn. 2021 Dec;30:1–9.
   Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79:685–699.
   PubMed Web of Science ®Google Scholar
• Burgers LE, Raza K, van der Helm-van Mil AH. Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives. RMD Open. 2019;5:e000870.
   PubMed Web of Science ®Google Scholar
• Rehberg M, Giegerich C, Praestgaard A, et al. Identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Rheumatol Ther. 2021 Dec;8:1661–1675.
   PubMed Web of Science ®Google Scholar
• Lee S, Kang S, Eun Y, et al. Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Res Ther. 2021 Oct 9;23:254.
   PubMed Web of Science ®Google Scholar
• Vodencarevic A, Tascilar K, Hartmann F, et al. Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs. Arthritis Res Ther. 2021 Feb 27;23:67.
   PubMedGoogle Scholar
• Thomson TM, Lescarbeau RM, Drubin DA, et al. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis. BMC Med Genomics. 2015 Jun 3;8:26.
   PubMed Web of Science ®Google Scholar
• Toonen EJ, Gilissen C, Franke B, et al. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One. 2012;7:e33199.
   PubMed Web of Science ®Google Scholar
• Arnell C, Bergman M, Basu D, et al. Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility. J Manag Care Spec Pharm. 2021;20:1–9.
   Google Scholar